中文名称 | 英文名称 | CAS号 | 化学式 | 分子量 |
---|---|---|---|---|
保护胸苷 | 5'-O-(4-4'-dimethoxytrityl)thymidine | 40615-39-2 | C31H32N2O7 | 544.604 |
中文名称 | 英文名称 | CAS号 | 化学式 | 分子量 |
---|---|---|---|---|
—— | 5'-O-(4-4'-dimethoxytrityl)-3'-O-levulinoyl-N3-pivaloyloxymethylthymidine | 196200-60-9 | C42H48N2O11 | 756.85 |
—— | [(2R,3S,5R)-2-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl] [(2R,3S,5R)-3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl methyl phosphate | 87007-52-1 | C42H47N4O14P | 862.827 |
—— | 5'-O-(4,4'-dimethoxytrityl)-3'-O-(5'-O-diisopropylsilylthymidyl)thymidine | 142554-09-4 | C47H58N4O12Si | 899.083 |
—— | 3'-O-levulinoylthymidine | 78635-98-0 | C15H20N2O7 | 340.333 |
—— | 1-{N3-[5'-O-(4,4'-dimethoxytrityl)-3'-O-(tert-butyldimethylsilyl)-thymidylyl]}-4-{N3-[5'-O-(allyloxycarbonyl)-thymidylyl]}butane | 1393343-42-4 | C55H70N4O14Si | 1039.26 |
—— | (2R,3S,5R)-2-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-5-(2-isobutyramido-6-oxo-1,6-dihydro-9H-purin-9-yl)tetrahydrofuran-3-yl (((2R,3S,5R)-3-hydroxy-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methyl) methyl phosphate | 93134-53-3 | C46H52N7O14P | 957.931 |
—— | N6-Benzoyl-P-methyl-5'-O-dimethoxytrityl-2'-deoxyadenosyl-(3'5')-2'-deoxythymidine | 82739-92-2 | C49H50N7O13P | 975.949 |
胸苷酰(3'->5')胸苷铵盐 | thymidylyl (3',5')thymidine | 1969-54-6 | C20H27N4O12P | 546.428 |
—— | dithymidine 2-hydroxyethyl-phosphate | 108351-08-2 | C22H31N4O13P | 590.481 |
A chimeric oligonucleotide tetramer and hexamer were synthesized by the phosphoramidite approach using a 2+2 and 3+3 strategy, respectively. The concept of convergent synthesis provides an efficient route toward the synthesis of longer chimeric oligonucleotides, such as small interfering RNA oligonucleotides without the pollution of n – 1 or shorter failures. This methodology offers an efficient and economical way to scale-up the synthesis of high purity oligonucleotides for clinical trials and commercial uses.